REVB

Revelation Biosciences (REVB)

Revelation Biosciences Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:REVB

1 2 3 4 5 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/12/03	22:38	Business Wire	Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds	NASDAQ:REVB	Revelation Biosciences Inc
2024/12/02	20:00	Business Wire	Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND	NASDAQ:REVB	Revelation Biosciences Inc
2024/11/12	20:00	Business Wire	Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply	NASDAQ:REVB	Revelation Biosciences Inc
2024/11/09	06:15	Business Wire	Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024	NASDAQ:REVB	Revelation Biosciences Inc
2024/09/24	19:00	Business Wire	Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10	NASDAQ:REVB	Revelation Biosciences Inc
2024/09/04	06:09	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:REVB	Revelation Biosciences Inc
2024/08/27	05:25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:REVB	Revelation Biosciences Inc
2024/08/22	06:30	Business Wire	Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds	NASDAQ:REVB	Revelation Biosciences Inc
2024/08/20	05:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:REVB	Revelation Biosciences Inc
2024/08/10	05:15	Business Wire	Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024	NASDAQ:REVB	Revelation Biosciences Inc
2024/08/03	05:11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:REVB	Revelation Biosciences Inc
2024/07/29	13:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:REVB	Revelation Biosciences Inc
2024/07/20	05:02	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:REVB	Revelation Biosciences Inc
2024/06/24	22:00	Business Wire	Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity	NASDAQ:REVB	Revelation Biosciences Inc
2024/06/13	22:21	Business Wire	Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini	NASDAQ:REVB	Revelation Biosciences Inc
2024/05/11	05:52	Business Wire	Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024	NASDAQ:REVB	Revelation Biosciences Inc
2024/03/23	05:15	Business Wire	Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023	NASDAQ:REVB	Revelation Biosciences Inc
2024/03/13	22:00	Business Wire	Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)	NASDAQ:REVB	Revelation Biosciences Inc
2024/03/12	22:00	Business Wire	Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference	NASDAQ:REVB	Revelation Biosciences Inc
2024/03/04	23:00	Business Wire	Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini	NASDAQ:REVB	Revelation Biosciences Inc
2024/02/14	10:12	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:REVB	Revelation Biosciences Inc
2024/02/13	23:00	Business Wire	Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)	NASDAQ:REVB	Revelation Biosciences Inc
2024/02/13	00:19	Edgar (US Regulatory)	Form SCHEDULE 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:REVB	Revelation Biosciences Inc
2024/02/09	06:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:REVB	Revelation Biosciences Inc
2024/02/06	06:41	Business Wire	Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering	NASDAQ:REVB	Revelation Biosciences Inc
2024/02/03	06:06	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:REVB	Revelation Biosciences Inc
2024/02/01	20:00	Business Wire	Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering	NASDAQ:REVB	Revelation Biosciences Inc
2024/02/01	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:REVB	Revelation Biosciences Inc
2024/01/31	07:21	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:REVB	Revelation Biosciences Inc
2024/01/31	05:32	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:REVB	Revelation Biosciences Inc